GUIZHOU XINBANG PHARMACEUTICAL CO., LTD.

Guizhou Xinbang Pharmaceutical Co., Ltd.

002390

CNE100000NG5

Pharmaceuticals

End-of-day quote Shenzhen S.E. Other stock markets 06:00:00 2024-04-25 pm EDT			5-day change	1st Jan Change
3.85 ^CNY	+1.05%		+4.34%	-13.29%

Apr. 15	Guizhou Xinbang Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	CI
Apr. 02	Tranche Update on Guizhou Xinbang Pharmaceutical Co., Ltd.'s Equity Buyback Plan announced on July 14, 2023.	CI

Guizhou Xinbang Pharmaceutical Co., Ltd. Approves Board Appointments

February 21, 2024 at 02:55 pm EST

Guizhou Xinbang Pharmaceutical Co., Ltd. announced that at its Extraordinary General Meeting of 2024 held on 20 February 2024, elected An Ji, Kong Lingzhong, Ding Yi, Ma Qianxian, Lv Xiangqian as non-independent director. Qiu Gang, Liu Jie, Liu Yifeng as independent director and Huang Yongjia, shareholder supervisor.

Latest news about Guizhou Xinbang Pharmaceutical Co., Ltd.

Guizhou Xinbang Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	Apr. 15	CI
Tranche Update on Guizhou Xinbang Pharmaceutical Co., Ltd.'s Equity Buyback Plan announced on July 14, 2023.	Apr. 01	CI
Guizhou Xinbang Pharmaceutical Co., Ltd. Approves Board Appointments	Feb. 21	CI
Xinbang Pharma Chairman Buys 14 Million Yuan More Shares	Jan. 04	MT
Tranche Update on Guizhou Xinbang Pharmaceutical Co., Ltd.'s Equity Buyback Plan announced on July 14, 2023.	Jan. 03	CI
Guizhou Xinbang Pharmaceutical Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023	23-10-29	CI
Tranche Update on Guizhou Xinbang Pharmaceutical Co., Ltd.'s Equity Buyback Plan announced on July 14, 2023.	23-10-09	CI
Guizhou Xinbang Pharmaceutical Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023	23-08-28	CI
Guizhou Xinbang Pharmaceutical Co., Ltd. commences an Equity Buyback Plan for 14,705,882 shares, representing 0.76% for CNY 200 million, under the authorization approved on July 13, 2023.	23-07-14	CI
Guizhou Xinbang Pharmaceutical Co., Ltd. authorizes a Buyback Plan.	23-06-26	CI
Guizhou Xinbang Pharmaceutical Co., Ltd.(SZSE:002390) dropped from Shenzhen Stock Exchange Component Index	23-06-09	CI
Guizhou Xinbang Pharmaceutical Co., Ltd.(SZSE:002390) dropped from Shenzhen Stock Exchange Component A Share Index	23-06-09	CI
Guizhou Xinbang Pharmaceutical Co., Ltd. Announces Cash Dividend on A Shares for the Year 2022, Payable on 30 May 2023	23-05-24	CI
Guizhou Xinbang Pharmaceutical Co., Ltd. Approves Final Dividend for 2022	23-05-15	CI
Guizhou Xinbang Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-04-28	CI
Guizhou Xinbang Pharmaceutical Co., Ltd. Proposes Final Dividend for 2022	23-04-18	CI
Guizhou Xinbang Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2022	23-04-17	CI
Guizhou Xinbang Pharmaceutical Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2022	22-10-28	CI
Guizhou Xinbang Pharmaceutical Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2022	22-08-24	CI
Guizhou Xinbang Pharmaceutical Co., Ltd. Announces Implementation of Final Cash Dividend for 2021, Payable on 24 May 2022	22-05-18	CI
Guizhou Xinbang Pharmaceutical Co., Ltd. Approves Cash Dividend	22-05-09	CI
Guizhou Xinbang Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2022	22-04-29	CI
Guizhou Xinbang Pharmaceutical Co., Ltd. Announces Final Cash Dividend Proposal for 2021	22-04-15	CI
Guizhou Xinbang Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2021	22-04-14	CI
Guizhou Kekai Medicine Co., Ltd. announced that it expects to receive CNY 461.450506 million in funding from Guizhou Xinbang Pharmaceutical Co., Ltd.	21-11-05	CI

Chart Guizhou Xinbang Pharmaceutical Co., Ltd.

Duration

Period

Chart Guizhou Xinbang Pharmaceutical Co., Ltd.

More charts

Company Profile

GUIZHOU XINBANG PHARMACEUTICAL Co., LTD is a China-based company, principally engaged in the research and development, manufacture and distribution of medical products. The Company operates its businesses through three segments. The Pharmaceutical Manufacturing segment is engaged in the manufacture and distribution of Chinese patent medicines, such as Ginkgo Leaves Tablets. The Pharmaceutical Distribution segment includes rapid wholesale business and medicine retail business. The Medical Services segment is engaged in the provision of medical services. It operates its businesses primarily in domestic markets.

Sector

Pharmaceuticals

Calendar

2024-04-28 - Q1 2024 Earnings Release

More about the company

Income Statement Evolution

More financial data

Annual profits - Rate of surprise

Company calendar

Sector Alternative Medicine

	1st Jan change	Capi.
GUIZHOU XINBANG PHARMACEUTICAL CO., LTD.	-13.29%	1.01B
DONG-E-E-JIAO CO.,LTD.	+35.04%	5.92B
SHIJIAZHUANG YILING PHARMACEUTICAL CO., LTD.	-15.13%	4.51B
TASLY PHARMACEUTICAL GROUP CO., LTD	-9.75%	3.15B
TIANJIN PHARMACEUTICAL DA REN TANG GROUP CORPORATION LIMITED	+2.14%	3.1B
SHANDONG BUCHANG PHARMACEUTICALS CO., LTD.	-6.82%	2.42B
HENAN LINGRUI PHARMACEUTICAL CO., LTD.	+47.87%	1.97B
GUANGYUYUAN CHINESE HERBAL MEDICINE CO., LTD.	-7.89%	1.68B
TIBET CHEEZHENG TIBETAN MEDICINE CO., LTD.	+0.09%	1.65B
TIANJIN CHASE SUN PHARMACEUTICAL CO.,LTD	-12.97%	1.53B

Alternative Medicine